Galapagos listed 10 years on Euronext Amsterdam and Brussels
May 06 2015 - 1:37AM
Galapagos NV (Euronext: GLPG) rings the opening bell
today at Euronext Amsterdam to celebrate 10 years as a listed
company.
Ten years ago, on 5 May 2005, Galapagos
completed its initial public offering with a dual listing in
Amsterdam and Brussels. Since then, Galapagos has grown from
70 to over 400 employees and from €70 million to around €1.2
billion in market capitalization. Galapagos forms part of the
Brussels BelMid Index and the Amsterdam Midcap Index.
Galapagos recently reported positive results with its JAK1
inhibitor filgotinib in the DARWIN 1 and DARWIN 2 trials in nearly
900 rheumatoid arthritis patients worldwide; this was one of the
research programs co-funded by the IPO in 2005.
About Galapagos Galapagos (Euronext:
GLPG; OTC: GLPYY) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule
medicines with novel modes of action, with a pipeline comprising
three Phase 2 programs, two Phase 1 trials, five pre-clinical
studies, and 25 discovery small-molecule and antibody programs in
cystic fibrosis, inflammation, and other indications. In the
field of inflammation, AbbVie and Galapagos signed a collaboration
agreement for the development and commercialization of
filgotinib. Filgotinib is an orally-available, selective
inhibitor of JAK1 for the treatment of rheumatoid arthritis and
potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. Galapagos
reported good activity and a favorable safety profile at 12 weeks
in both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos
also signed a collaboration agreement in cystic fibrosis to develop
and commercialize molecules that address mutations in the CFTR
gene. Potentiator GLPG1837 is currently in a Phase 1 trial,
and corrector GLPG2222 is at the pre-clinical candidate
stage. GLPG1205, a first-in-class inhibitor of GPR84 and
fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of
autotaxin, has shown favorable safety in a Phase 1 trial and is
expected to enter Phase 2 in idiopathic pulmonary fibrosis.
The Galapagos Group, including fee-for-service subsidiary Fidelta,
has approximately 400 employees, operating from its Mechelen,
Belgium headquarters and facilities in The Netherlands, France, and
Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV Elizabeth Goodwin, Head of
Corporate Communications & IR Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements This release may
contain forward-looking statements, including, without limitation,
statements concerning anticipated progress, objectives and
expectations regarding the commercial potential of our product
candidates, intended product development, clinical activity timing,
and other objectives and explanations, all of which involve certain
risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as
"believes," "anticipates," "expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Among the factors that may result in differences are
the inherent uncertainties associated with competitive
developments, clinical trial and product development activities,
regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
HUG#1919059
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024